SEC Comment Letter 0000000000-24-005503 to Erasca, Inc. (ERAS)
Erasca, Inc.
Date: May 14, 2024 · CIK: 0001761918 · Accession: 0000000000-24-005503
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279261
Letter
United States securities and exchange commission logo May 14, 2024 Jonathan E. Lim, M.D. Chairman and Chief Executive Officer Erasca, Inc. 3115 Merryfield Row, Suite 300 San Diego, California 92121 Re:Erasca, Inc. Registration Statement on Form S-3 Filed May 9, 2024 File No. 333-279261 Dear Jonathan E. Lim: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cheston J. Larson, Esq.
Show Raw Text
United States securities and exchange commission logo
May 14, 2024
Jonathan E. Lim, M.D.
Chairman and Chief Executive Officer
Erasca, Inc.
3115 Merryfield Row, Suite 300
San Diego, California 92121
Re:Erasca, Inc.
Registration Statement on Form S-3
Filed May 9, 2024
File No. 333-279261
Dear Jonathan E. Lim:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Cheston J. Larson, Esq.